Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT05972135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05972135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
October 23, 2023
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma